Home Publications About the Authors
About the Authors
This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode standard for trustworthy health information:
verify here.
Deutsch Englisch
Contact Impressum Data Protection Login
Home Publications About the Authors
About the Authors
This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode standard for trustworthy health information:
verify here.
Deutsch Englisch
Contact Impressum Data Protection Login
Dr. Quinzler, Renate
Referentin für Pharmakoepidemiologie [bis 2010], Deutschen Arzneiprüfungsinstitut e. V. (DAPI), Eschborn [bis 2010]
März 2008
Fachapothekerin für Arzneimittelinformation
Februar 2008 - Mai 2010
Referentin für Pharmakoepidemiologie am Deutschen Arzneiprüfungsinstitut (DAPI), Eschborn
Dezember 2007
Promotion zum Dr. sc. hum.
seit Februar 2004
Wissenschaftliche Mitarbeiterin, Universitätsklinikum Heidelberg, Abteilung Innere Medizin VI, Klinische Pharmakologie und Pharmakoepidemiologie
Juli 2002 - Februar 2004
Apothekerin in einer öffentlichen Apotheke
Juni 2002
Approbation als Apothekerin
Publications:
Incidence of thyroid hormone therapy in patients treated with sorafenib or sunitinib
Effect of generic switch on pharmacy refill compliance after ramipril patent expiry – a retrospective study using the DAPI database
Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in Type-2 diabetic patients: comparison of insulin glargine with NPH insulin.
Generic switch after ramipril patent expiry is not associated with decreased pharmacy refill compliance: a retrospective study using the DAPI database.
Impact of risk communications and market withdrawals on prescribing of cyclooxygenase-2 inhibitors and non-selective nonsteroidal anti-inflammatory drugs
Aktuelle Verordnungen von COX-2-Hemmern in Deutschland
Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany
Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany
Beeinflusst die Umstellung von Risedronat oder Alendronat Originalprodukten auf Generika die Compliance (Persistenz)?
Persistence with basal supported oral therapy - comparison of insulin glargine versus NPH insulin.
Persistence with basal supported oral therapy - comparison of insulin glargine versus NPH insulin.
Non-Compliance – das unterschätzte Problem: Neue Möglichkeiten der Erfassung über Datenbankanalysen
Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study.